AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35022086 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz over the right DLPFC, 2000 pulses per day)
Number of subjects: 144
Study 35022086 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 144
Study 35022086 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 144
Study 35022159 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 64
Study 35022159 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of BNT162b2 vaccine
Number of subjects: 64
Study 35022299 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1227
Study 35022304 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity and moderate to vigorous exercise levels
Number of subjects: 237
Study 35022304 — intervention group
Group type: EXPERIMENTAL
Intervention: High regular physical activity levels and exercise habits
Number of subjects: 237
Study 35022321 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg orally weekly) in arm A (PC-PG)
Number of subjects: 30
Study 35022321 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg orally weekly) in arm B (other neuroendocrine tumors)
Number of subjects: 30
Study 35022321 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg orally on 2 consecutive days each week) in arm C (PC-PG)
Number of subjects: 30
Study 35022321 — intervention group
Group type: COMPARATOR
Intervention: Karnofsky performance status
Number of subjects: 30
Study 35022321 — intervention group
Group type: COMPARATOR
Intervention: Treatment-related adverse events
Number of subjects: 30
Study 35022322 — intervention group
Group type: EXPERIMENTAL
Intervention: oHSV treatment with NOTCH blockade
Number of subjects: 0
Study 35022322 — intervention group
Group type: COMPARATOR
Intervention: oHSV treatment
Number of subjects: 0
Study 35022448 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmTOR (biodegradable nanoparticles-encapsulating rapamycin)
Number of subjects: 0
Study 35022448 — intervention group
Group type: EXPERIMENTAL
Intervention: pegadricase (an immunogenic, pegylated uricase enzyme)
Number of subjects: 0
Study 35022448 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmTOR and pegadricase combination
Number of subjects: 0
Study 35022711 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SARS-CoV-2 antibodies (IgA, IgM, IgG, and/or total Ig)
Number of subjects: 204
Study 35022711 — intervention group
Group type: COMPARATOR
Intervention: Absence of SARS-CoV-2 antibodies
Number of subjects: 204
Study 35022711 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of viral RNA
Number of subjects: 204
Study 35022711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer days since symptom onset
Number of subjects: 204
Study 35022790 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with ACE inhibitors (ACEis)
Number of subjects: 114
Study 35022790 — intervention group
Group type: COMPARATOR
Intervention: Untreated hemizygous patients
Number of subjects: 114
Study 35022790 — intervention group
Group type: COMPARATOR
Intervention: Very late treated hemizygotes
Number of subjects: 114
Study 35022790 — intervention group
Group type: COMPARATOR
Intervention: Untreated heterozygotes
Number of subjects: 114
Study 35022790 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated heterozygous females
Number of subjects: 114
Study 35023065 — intervention group
Group type: EXPERIMENTAL
Intervention: Seed-based resting-state functional connectivity (RsFc) analysis using three cerebellar regions of interest (ROIs)
Number of subjects: 247
Study 35023065 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 247
Study 35023343 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-bore transradial access (TRA)
Number of subjects: 343
Study 35023343 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-bore transfemoral access (TFA)
Number of subjects: 343
Study 35023363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericoronary FAI values >-70.1 Hounsfield units
Number of subjects: 130
Study 35023363 — intervention group
Group type: COMPARATOR
Intervention: Lesions with pericoronary FAI values <=-70.1 Hounsfield units
Number of subjects: 130
Study 35023844 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital stories (2- to 3-minute self-made videos)
Number of subjects: 0
Study 35023844 — intervention group
Group type: COMPARATOR
Intervention: Video testimonies (created by professional filmmakers)
Number of subjects: 0
Study 35024196 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome-based predictive model
Number of subjects: 462
Study 35024196 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome data added to clinical parameters
Number of subjects: 462
Study 35024196 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome-based risk score including the ten most discriminant genera
Number of subjects: 462
Study 35024375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 100
Study 35024375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 100
Study 35024375 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study 35024776 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 651
Study 35024776 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 651
Study 35025062 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib (3 mg twice daily, 6 mg twice daily, 12 mg once daily)
Number of subjects: 0
Study 35025062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35025128 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-O blood group
Number of subjects: 1789
Study 35025128 — intervention group
Group type: COMPARATOR
Intervention: Group O
Number of subjects: 1789
Study 35025555 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered attentional bias modification (ABM) training for 13 days as an adjunct to smoking cessation treatment
Number of subjects: 0
Study 35025555 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 35025756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperglycemics
Number of subjects: 521
Study 35025756 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported severe and nonsevere hypoglycemia incidence
Number of subjects: 521
Study 35025756 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hypoglycemia data
Number of subjects: 521
Study 35025762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Number of subjects: 0
Study 35025762 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine supplementation
Number of subjects: 0
Study 35025898 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care approach
Number of subjects: 0
Study 35025898 — intervention group
Group type: COMPARATOR
Intervention: Telesupport approach
Number of subjects: 0
Study 35025909 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 24
Study 35025909 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load monitoring
Number of subjects: 24
Study 35025909 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV partner notification services
Number of subjects: 24
Study 35025909 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of pre-exposure prophylaxis (PrEP)
Number of subjects: 24
Study 35025987 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra leadless pacemaker implantation
Number of subjects: 2817
Study 35026142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks
Number of subjects: 399
Study 35026411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 36
Study 35026476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib (LBPD) continued beyond progressive disease
Number of subjects: 102
Study 35026597 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 404
Study 35026597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical insight
Number of subjects: 404
Study 35026597 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 404
Study 35026597 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 404
Study 35026992 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nomogram for postoperative AKI
Number of subjects: 843
Study 35026992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 843
Study 35026992 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary risk score
Number of subjects: 843
Study 35026992 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of nomogram
Number of subjects: 843
Study 35026992 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis
Number of subjects: 843
Study 35027018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social acceptance among peers
Number of subjects: 775
Study 35027018 — intervention group
Group type: COMPARATOR
Intervention: Psychological distress
Number of subjects: 775
Study 35027038 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucarpidase 2000u
Number of subjects: 8
Study 35027038 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucarpidase 1000u
Number of subjects: 8
Study 35027038 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with glucarpidase
Number of subjects: 8
Study 35027038 — intervention group
Group type: COMPARATOR
Intervention: MTX-based therapy
Number of subjects: 8
Study 35027051 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA-based HCC screening model
Number of subjects: 120
Study 35027051 — intervention group
Group type: COMPARATOR
Intervention: serum α-fetoprotein (AFP)
Number of subjects: 120
Study 35027114 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl
Number of subjects: 0
Study 35027114 — intervention group
Group type: COMPARATOR
Intervention: Background Statin Type
Number of subjects: 0
Study 35027313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DNA-damaging therapy and immunotherapy
Number of subjects: 0
Study 35027438 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (507 girls)
Number of subjects: 910
Study 35027438 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID-19 cohort (403 girls)
Number of subjects: 910
Study 35027474 — intervention group
Group type: EXPERIMENTAL
Intervention: New CVS+ lesions
Number of subjects: 153
Study 35027474 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhancing lesions
Number of subjects: 153
Study 35027474 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 153
Study 35027474 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CVS+ percentage at baseline
Number of subjects: 153
Study 35027656 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA positivity (≥10% tumor fraction by LPWGS) after two cycles of treatment
Number of subjects: 45
Study 35027656 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA negativity (tumor-negative) after two cycles of treatment
Number of subjects: 45
Study 35027656 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA as an independent risk factor
Number of subjects: 45
Study 35027752 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran (9 mg or higher)
Number of subjects: 0
Study 35027752 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran (single doses)
Number of subjects: 0
Study 35027752 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran (dose-escalation trial)
Number of subjects: 0
Study 35027752 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpasiran (in transgenic mice and cynomolgus monkeys)
Number of subjects: 0
Study 35027909 — intervention group
Group type: EXPERIMENTAL
Intervention: A1c ≥7%
Number of subjects: 217
Study 35027909 — intervention group
Group type: COMPARATOR
Intervention: A1c <7%
Number of subjects: 217
Study 35028514 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained champions in nutrition care improvements
Number of subjects: 14
Study 35028514 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation toolkit, audit and feedback, community of practice with external mentorship
Number of subjects: 14
Study 35028608 — intervention group
Group type: EXPERIMENTAL
Intervention: PEC-01 cells implanted subcutaneously in VC-02 macroencapsulation devices
Number of subjects: 17
Study 35028659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline and/or Delamanid
Number of subjects: 2296
Study 35028659 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectables
Number of subjects: 2296
Study 35028659 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 2296
Study 35028673 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and caffeine among preterm infants
Number of subjects: 624249
Study 35028673 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant, caffeine, and probiotics
Number of subjects: 624249
Study 35028673 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone and ranitidine
Number of subjects: 624249
Study 35028673 — intervention group
Group type: EXPERIMENTAL
Intervention: General drug utilisation patterns
Number of subjects: 624249
Study 35028673 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-evidence-based drugs
Number of subjects: 624249
Study 35028673 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational drug use
Number of subjects: 624249
Study 35028730 — intervention group
Group type: EXPERIMENTAL
Intervention: sCMV
Number of subjects: 54
Study 35028730 — intervention group
Group type: COMPARATOR
Intervention: CTL
Number of subjects: 54
Study 35029044 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver volume (LV) based prediction model (LEAP-HBV)
Number of subjects: 486
Study 35029044 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated liver volume (ELV)
Number of subjects: 486
Study 35029044 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 486
Study 35029189 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib plus methotrexate (MTX)
Number of subjects: 155
Study 35029517 — intervention group
Group type: EXPERIMENTAL
Intervention: MB SENSE DWI
Number of subjects: 0
Study 35029517 — intervention group
Group type: COMPARATOR
Intervention: cDWI
Number of subjects: 0
Study 35029534 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless blood alcohol concentration device
Number of subjects: 0
Study 35029534 — intervention group
Group type: COMPARATOR
Intervention: No access to the breathalyzer (Control)
Number of subjects: 0
Study 35029661 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-living gait cadence measured by wearable accelerometers
Number of subjects: 432
Study 35029661 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-living gait cadence measured by wearable accelerometers in higher-functioning participants (cadence ≥100 steps/minute)
Number of subjects: 432
Study 35029661 — intervention group
Group type: COMPARATOR
Intervention: Traditional in-clinic measures of mobility
Number of subjects: 432
Study 35029661 — intervention group
Group type: EXPERIMENTAL
Intervention: All metrics in participants with slow baseline gait (gait speed <0.8 m/s)
Number of subjects: 432
Study 35029841 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised foot orthoses (CFOs)
Number of subjects: 1058
Study 35029841 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (PFOs)
Number of subjects: 1058
Study 35029868 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of subarachnoid oxygen electrode, pressure probe, and microdialysis catheter.
Number of subjects: 26
Study 35030070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study 35030070 — intervention group
Group type: COMPARATOR
Intervention: Control group (without BPD)
Number of subjects: 0
Study 35030090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game
Number of subjects: 1004
Study 35030090 — intervention group
Group type: COMPARATOR
Intervention: Brainilis control game
Number of subjects: 1004
Study 35030234 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU Vitamin A Supplementation (VAS) administered before and 4 weeks after measurement
Number of subjects: 94
Study 35030235 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanoid avatars generated for representative adults with characteristics based on body mass, height, age, and waist circumference
Number of subjects: 570
Study 35030235 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanoid avatars developed at ∼20-y intervals for representative males and females
Number of subjects: 570
Study 35030235 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional series of developed avatars at key BMI cutoffs
Number of subjects: 570
Study 35031072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care
Number of subjects: 40
Study 35031227 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg IV in cycle 1, followed by obinutuzumab plus atezolizumab 1200 mg IV for cycles 2-8, and atezolizumab only from cycle 9.
Number of subjects: 49
Study 35031227 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus atezolizumab 1200 mg IV
Number of subjects: 49
Study 35031227 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks (RP2D)
Number of subjects: 49
Study 35031416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus A16 inoculation in subjects with allergic rhinitis
Number of subjects: 0
Study 35031416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus A16 inoculation in subjects with asthma
Number of subjects: 0
Study 35031416 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls inoculated with rhinovirus A16
Number of subjects: 0
Study 35031545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg/day plus Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 30
Study 35031547 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-I7 (10 mg/kg on the final day of RT)
Number of subjects: 0
Study 35031547 — intervention group
Group type: EXPERIMENTAL
Intervention: RT (1.8 Gy/day × 5 days) + NT-I7
Number of subjects: 0
Study 35031547 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-I7
Number of subjects: 0
Study 35031547 — intervention group
Group type: COMPARATOR
Intervention: Depleting CD8 T cells
Number of subjects: 0
Study 35032132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 0
Study 35032132 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35032246 — intervention group
Group type: EXPERIMENTAL
Intervention: Community support for health care providers measuring alcohol consumption
Number of subjects: 260
Study 35032562 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 34
Study 35032664 — intervention group
Group type: EXPERIMENTAL
Intervention: Daraja intervention (five sessions delivered by a social worker over a 3-month period)
Number of subjects: 500
Study 35032664 — intervention group
Group type: COMPARATOR
Intervention: Standard of care HIV linkage
Number of subjects: 500
Study 35032682 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 106
Study 35032682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 106
Study 35032682 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 106
Study 35032696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundal height measurement during routine antenatal visits
Number of subjects: 0
Study 35032696 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound during routine antenatal visits
Number of subjects: 0
Study 35032916 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Baecke Physical Activity Questionnaire (mBQ)
Number of subjects: 100
Study 35033008 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (nCRT) using MRI guided radiotherapy (MRgRT) with 55 Gy in 25 fractions on Gross Tumor Volume (GTV) and 45 Gy in 25 fractions on drainage nodes, along with continuous chemotherapy with 5-fluoracil (5-FU) or oral capecitabine.
Number of subjects: 0
Study 35033008 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI guided radiotherapy (MRgRT) with dose escalation based on early tumour regression index (ERI).
Number of subjects: 0
Study 35033042 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal radiologists and orthopaedic spine surgeons evaluating MRI findings
Number of subjects: 102
Study 35033042 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of dural sac cross-sectional area
Number of subjects: 102
Study 35033042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement for all parameters
Number of subjects: 102
Study 35033047 — intervention group
Group type: EXPERIMENTAL
Intervention: New toric intraocular lens (IOL) with anchor-wing haptics (NS60YT)
Number of subjects: 53
Study 35033055 — intervention group
Group type: EXPERIMENTAL
Intervention: PASHOS Test (clinical test including body mass index, neck circumference, and observed apneas during sleep)
Number of subjects: 194
Study 35033055 — intervention group
Group type: EXPERIMENTAL
Intervention: PASHOS Test with added oxygen desaturation index (ODI) from HSAT (ODI3% ≥ 15%)
Number of subjects: 194
Study 35033092 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg once daily (qd) as part of triple combined antiretroviral therapy (cART)
Number of subjects: 100
Study 35033092 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg qd
Number of subjects: 100
Study 35033176 — intervention group
Group type: EXPERIMENTAL
Intervention: Music & Memory (M&M) intervention implemented using a standardized manual, staff trainings, and iPods for residents.
Number of subjects: 27
Study 35033176 — intervention group
Group type: EXPERIMENTAL
Intervention: Music & Memory (M&M) intervention
Number of subjects: 27
Study 35033178 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 40
Study 35033178 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 40